Roles of immune dysregulation in MASLD
Tingyu Dong, Jiajin Li, Yuqing Liu, Shikai Zhou, Xiang Wei, Hongting Hua, Kechao Tang, Xiaomin Zhang, Yiming Wang, Zhen Wu, Chaobing Gao, Huabing Zhang
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Its occurrence and progression involve the process from simple hepatic steatosis to metabolic dysfunction associated steatohepatitis (MASH), which could develop into advanced liver fibrosis, cirrhosis, or hepatocellular carcinoma (HCC). Growing evidences support that the pathogenesis and progression of MASLD are closely related to immune system dysfunction. This review aims to summarize the association of MASLD with immune disorders and the prospect of using immunotherapy for MASLD.